Login to Your Account

Other News To Note

Wednesday, April 27, 2011
RXi Pharmaceuticals Corp., of Worcester, Mass., received two SBIR grants from the National Institutes of Health. A $304,559 Phase I grant from the National Institute of Neurological Disorders and Stroke will fund an ongoing collaboration with the University of Massachusetts Medical School to develop RNAi therapeutics for amyotrophic lateral sclerosis and other neurodegenerative disorders.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription